PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 9, 2026Cureus0 citationsOpen Access

Safety And Efficacy Of Stereotactic Body Radiotherapy For Central Non-Small Cell Lung Cancer

Safety and Efficacy of Stereotactic Body Radiotherapy for Centrally Located Early-Stage Non-small Cell Lung Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

MRMirudhula Chitra RameshMPMahadev PotharajuTRT Raja

Discussion

Loading...

Member takes

Overview

Randomized trial evaluates tumor control in central non-small cell lung cancer, indicating a safe option for inoperable cases.

Key Points

  • This study aims to evaluate the safety and effectiveness of stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer.
  • 41 patients with early-stage central NSCLC treated with SBRT from January 2019 to December 2023.
  • SBRT was administered at a dose of 8 Gy in 8 fractions (total 64 Gy).
  • Key outcomes included freedom from local progression at three years and other survival metrics.
  • Three-year freedom from local progression was 85.9% (95% CI: 66.1%-94.5%).
  • Three-year overall survival was 68.6% (95% CI: 48.7%-82.1%).
  • Minimal treatment-related toxicity was observed (grade ≥ 2 in 1 patient, 2.4%).

Cite This Study

Ramesh et al. (2026) studied this question.

synapsesocial.com/papers/69fed0abb9154b0b82877c6ehttps://doi.org/10.7759/cureus.108408
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-World Data on the Safety and Efficacy of SBRT for Central and Ultra-Central Lung Tumors: A Retrospective Multi-Center Cohort2026
  2. 2Stereotactic Radiation for Ultra-Central Non-Small Cell Lung Cancer: A Safety and Efficacy Trial (SUNSET)2024 · 41 citations
  3. 3Outcome and safety of SBRT in centrally and ultra-centrally located lung tumours: A PRISMA-based systematic review and Meta-Analysis2026
  4. 4Oncological Results and Toxicities of Stereotactic Body Radiotherapy in Ultracentral Lung Tumors2024
  5. 5Precision Stereotactic Body Radiotherapy for Ultra‐Central NSCLC: Tailored Margins Reduce Toxicity Without Compromising Tumor Control2026